PACB stock reflects Illumina merger plan as investors weigh 2025 revenue outlook

Pacific Biosciences of California Inc. (ISIN US6932471010) is the company behind PACB stock on Nasdaq and is currently in the spotlight as investors digest its planned all-stock merger with Illumina and the latest financial guidance for 2024 and 2025.

Revenue up 43 percent in 2023

According to the companys annual report for 2023, Pacific Biosciences generated revenue of $195.9 million in fiscal 2023, an increase of 43 percent compared with $137.0 million in 2022.

The same filing shows that the company reported a net loss of $336.6 million for 2023, slightly narrower than the $379.6 million net loss reported in 2022, highlighting that strong top-line growth has not yet translated into profitability.

Illumina deal and 2025 targets

In late 2024, Pacific Biosciences and Illumina announced that they had entered into a definitive agreement under which Illumina will acquire Pacific Biosciences in an all-stock transaction, subject to regulatory approval and customary closing conditions.

In connection with the proposed deal, Pacific Biosciences outlined a medium-term outlook indicating that it aims to grow annual revenue toward a range around $500 million in 2025, well above the $195.9 million achieved in 2023, while working to narrow operating losses over the same period.

Sequel and Revio systems drive growth

The companys revenue is primarily generated by sales of its sequencing instruments and consumables, including the Sequel family and the more recent Revio system, which targets higher throughput for whole-genome and transcriptome applications.

Management has highlighted that instrument placements in 2023 and early 2024 are expected to increase recurring consumables revenue over time, supporting the companys ambition to reach annual revenue well above the 2023 baseline as more customers ramp utilization.

PACB stock on Nasdaq

PACB stock is listed on Nasdaq under the symbol PACB and gives investors exposure to Pacific Biosciences position in long-read DNA sequencing technology.

With a market capitalization in the low to mid single-digit billion dollar range in recent months and annual revenue of $195.9 million in 2023, the valuation reflects expectations that the combination with Illumina and continued adoption of Revio and related consumables can drive substantial top-line expansion over the next several years.